Revelation Biosciences Schedules Shareholder Vote on Reverse Stock Split to Maintain Nasdaq Listing
Summary
Revelation Biosciences filed its definitive proxy statement, scheduling a shareholder meeting on June 24, 2026, to vote on a reverse stock split proposal with a wide ratio range (1-for-2 to 1-for-250) aimed at maintaining Nasdaq listing compliance.
Key Events
-
Shareholder Meeting Scheduled
The definitive proxy statement sets the Annual Meeting of Stockholders for June 24, 2026, where key proposals will be voted on.
-
Reverse Stock Split Proposal
Shareholders will vote on authorizing the board to effect a reverse stock split with a ratio between 1-for-2 and 1-for-250 within one year, primarily to regain or maintain Nasdaq minimum bid price compliance.
-
History of Reverse Splits
This proposal follows previous reverse stock splits of 1-for-16 (January 2025), 1-for-3 (July 2025), and 1-for-4 (January 2026), indicating a recurring struggle with Nasdaq listing requirements.
-
Ongoing Going Concern Warning
The company's recent 10-Q (May 7, 2026) reiterated a going concern warning, highlighting its precarious financial position.
Analysis
Revelation Biosciences has filed its definitive proxy statement, setting the stage for a critical shareholder vote on a reverse stock split. This action is crucial for the micro-cap company, which has a history of multiple reverse splits and ongoing going concern warnings, to maintain its Nasdaq listing. The wide potential ratio for the split (up to 1-for-250) underscores the severity of the company's stock price challenges and the significant potential for further share consolidation.
At the time of this filing, REVB was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.88 to $40.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.